Trials / Conditions / Acute Myeloid Leukaemia

Acute Myeloid Leukaemia

29 registered clinical trials studyying Acute Myeloid Leukaemia — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematolog NCT07155226	AstraZeneca	Phase 1 / Phase 2
Recruiting	Clinical Study of U32 in Patients With Acute Myeloid Leukemia NCT07036250	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd	Phase 1 / Phase 2
Recruiting	Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation NCT06793410	Vastra Gotaland Region	Phase 2
Not Yet Recruiting	Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standa NCT06848270	Universidade do Porto	N/A
Recruiting	Leukemia Adapted Protocol NCT06928909	Baylor College of Medicine	—
Completed	Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) NCT06326697	Hikma Pharmaceuticals LLC	Phase 1
Recruiting	MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) NCT06345365	Zhongnan Hospital	Phase 3
Terminated	A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute NCT05712278	Sanofi	Phase 1
Completed	GITMO AML/MDS-Relapse Registry Study NCT06790680	Gruppo Italiano Trapianto di Midollo Osseo	—
Recruiting	Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation NCT06892223	Istituto Clinico Humanitas	Phase 2
Completed	Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia NCT04629443	Institut de Recherches Internationales Servier	Phase 1 / Phase 2
Unknown	A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT NCT04217278	University of Birmingham	Phase 2 / Phase 3
Withdrawn	Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia NCT04106076	Cellectis S.A.	Phase 1
Completed	Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Ven NCT03672695	Institut de Recherches Internationales Servier	Phase 1
Terminated	Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination NCT03217838	AstraZeneca	Phase 1
Recruiting	International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia NCT02724163	University of Birmingham	Phase 3
Unknown	Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations NCT02272478	Cardiff University	Phase 2 / Phase 3
Unknown	Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are NCT02189824	University of Sydney	Phase 1
Completed	Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With NCT02844257	Hospices Civils de Lyon	—
Completed	Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers NCT01597219	University College, London	Phase 2
Completed	WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study NCT01621724	Cell Medica Ltd	Phase 1 / Phase 2
Completed	A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor P NCT01236144	Cardiff University	Phase 1 / Phase 2
Completed	Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) NCT01422603	University Hospital Southampton NHS Foundation Trust	Phase 1 / Phase 2
Unknown	Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Sy NCT01716364	Peter MacCallum Cancer Centre, Australia	Phase 1
Completed	An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) NCT01019161	AstraZeneca	Phase 1
Completed	Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) NCT00530699	AstraZeneca	Phase 1
Completed	Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>6 NCT01497002	University of Leipzig	Phase 3
Completed	Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) NCT01063660	medac GmbH	Phase 2
Unknown	Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<6 NCT01414231	University of Leipzig	Phase 3